The subsidiary company of Vienna-based Haplogen was purchased by the british Horizon Discovery group. Halogen develops new therapies for infection with their technology that produces human cells. Horizon, on the other hand, is a market leader in the area of genome editing and will develop further the business in Vienna under the name Horizon Genomics.
„For us, the perfect fit of the corporate cultures was important. Horizon Discovery was founded in 2008 and grew to over 200 employees but it hasn’t lost the startup culture and dynamics which are important for international growth,” said Dr. Thomas Moser, CEO of the new Horizon Genomics GmbH.
